Are there treatments for SLC6A3-related dopamine transporter deficiency syndrome?

Information about treatment is currently limited for this condition.

What complications can arise from SLC6A3-related dopamine transporter deficiency syndrome?

SLC6A3-related dopamine transporter deficiency syndrome can lead to various complications due to its movement problems. These may include difficulty with daily activities, challenges in walking, and issues with balance. Over time, the symptoms can progress, making it harder for individuals to manage their movements and perform tasks independently.

What is the prognosis for someone with SLC6A3-related dopamine transporter deficiency syndrome?

The prognosis for SLC6A3-related dopamine transporter deficiency syndrome is currently not well understood, as there is limited information available. The age of onset and severity of symptoms can vary widely among individuals. This means that some may have a milder form of the condition, while others may experience more significant challenges.

Are there any specific specialists that should be involved in the care of someone with SLC6A3-related dopamine transporter deficiency syndrome?

Individuals with SLC6A3-related dopamine transporter deficiency syndrome may benefit from seeing specialists who understand movement disorders. Neurologists, particularly those with experience in genetic conditions, can provide valuable insights and support. Occupational and physical therapists can also help with managing movement difficulties and improving daily functioning.

Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

SLC6A3-related dopamine transporter deficiency syndrome (DTDS) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

SLC6A3-related dopamine transporter deficiency syndrome

MONDO:0700117

Also known as:DTDSDopamine transporter deficiency syndrome

Overview

A complex movement disorder characterized by tremor, rigidity, bradykinesia, chorea, reduced facial expression, and Parkinsonism-dystonia. This disease is caused by loss of function variants in the SLC6A3 gene, which impair the dopamine transporter protein. The onset of this disease ranges from infancy to adulthood.

OnsetINFANTILE

TreatmentsNo approved treatments · 1 in pipeline

ResearchLimited published research (9 articles)

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

No HPO annotations are available for this condition.

Age of onset: infancy.

GeneReviews

Clinical Guidance

SLC6A3-related dopamine transporter deficiency syndrome (DTDS) typically presents in infancy and atypically later in childhood, adolescence, or adulthood. In early-onset SLC6A3-related DTDS, nonspecific findings of irritability, feeding difficulties, axial hypotonia, and/or delayed motor development are followed by onset of hyperkinetic movement disorder, abnormal eye movements, and childhood parkinsonism-dystonia. Later-onset SLC6A3-related DTDS is characterized by normal psychomotor development in infancy and early childhood. Attention-deficit/hyperactivity disorder (ADHD) is reported in childhood followed by later-onset manifestations of parkinsonism-dystonia with tremor, progressive bradykinesia, variable tone, and dystonic posturing.

Diagnosis

Drawn from GeneReviews diagnostic guidelines, newborn screening panel status (RUSP), and ClinGen gene-disease validity classifications. Reflects current clinical evidence and consensus where available.

GeneReviews

Diagnostic Criteria

Suggestive Findings

Classic early-onset and atypical later-onset SLC6A3-related dopamine transporter deficiency syndrome (DTDS) should be suspected in individuals with the following clinical and laboratory findings.

Clinical Findings

Classic early-onset DTDS

• Predominant features in infancy

Onset usually within the first six months of life

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for SLC6A3-related dopamine transporter deficiency syndrome. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for SLC6A3-related dopamine transporter deficiency syndrome, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for SLC6A3-related dopamine transporter deficiency syndrome. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Prognosis

Based on GeneReviews surveillance recommendations, HPO phenotype frequency and severity annotations, and published prevalence estimates from Orphanet and OMIM.

GeneReviews

Surveillance Guidelines

To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 5. SLC6A3-Related Dopamine Transporter Deficiency Syndrome: Recommended Surveillance

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for SLC6A3-related dopamine transporter deficiency syndrome.

9 publications have been identified in PubMed for SLC6A3-related dopamine transporter deficiency syndrome. Research spans Basic Science / Preclinical (44%), Review / Meta-Analysis (33%), and Case Report / Case Series (11%).

Recent Publications

Budinger D (2026). [PMID: 41633979](https://pubmed.ncbi.nlm.nih.gov/41633979/). *Nat Commun*. [Basic Science / Preclinical]
Russo EE (2026). [PMID: 41699258](https://pubmed.ncbi.nlm.nih.gov/41699258/). *EMBO Mol Med*. [Basic Science / Preclinical]
Al Sari RR (2025). [PMID: 40291937](https://pubmed.ncbi.nlm.nih.gov/40291937/). *J Med Life*. [Review / Meta-Analysis]
Mabry SJ (2025). [PMID: 41051712](https://pubmed.ncbi.nlm.nih.gov/41051712/). *Adv Neurobiol*. [Review / Meta-Analysis]
Sartorelli J (2025). [PMID: 39985571](https://pubmed.ncbi.nlm.nih.gov/39985571/). *J Neurol*. [Review / Meta-Analysis]

Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 5:52 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→What is the current development status of adeno-associated viral vector serotype 2 containing the human SLC6A3 gene, and when might it become available?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

FAQ

Frequently Asked Questions

Common questions about SLC6A3-related dopamine transporter deficiency syndrome

SLC6A3-related dopamine transporter deficiency syndrome is a complex movement disorder. It shows up as problems with movement like tremor, stiffness, slow movements (bradykinesia), involuntary movements (chorea), reduced facial expression, and symptoms similar to Parkinsonism-dystonia. These issues arise because the dopamine transporter protein does not work correctly. This condition is caused by changes in the SLC6A3 gene that reduce the function of the dopamine transporter. This defect affects how dopamine, a chemical important for controlling movement, is regulated in the brain. The age when symptoms begin can vary widely from infancy to adulthood, making each case unique.

People with this condition may experience a range of movement problems including tremor, rigidity (stiffness), slow movements (bradykinesia), involuntary movements (chorea), and reduced facial expression. These signs are typical of the condition as described in the available information.

This disorder is linked to loss of function variants in the SLC6A3 gene. These genetic changes lead to an impaired dopamine transporter protein, which affects the normal movement of dopamine in the brain. This disrupted dopamine transport is key to the movement difficulties experienced in the condition. Associated genes include SLC6A3.

← Back to All Diseases

GeneReviews

Differential Diagnosis

Hereditary and acquired disorders can present clinically with the manifestations of classic early-onset and atypical later-onset SLC6A3-related dopamine transporter deficiency syndrome (DTDS). Table 2. Genes of Interest in the Differential Diagnosis of SLC6A3-Related Dopamine Transporter Deficiency Syndrome

Gene	Disorder	MOI	Comment
Aromatic L-amino acid decarboxylase deficiency	AR	Clinical features assoc w/SLC6A3-related DTDS (progressive parkinsonism-dystonia, eye movement disorder, axial hypotonia, delayed motor development) may be similar to those seen in other neurotransmitter disorders.1,2	—
DNACJ12	Hyperphenylalaninemia, non-BH4 deficient (OMIM 617384)	AR	—
GCH1	GTP cyclohydrolase 1-deficient dopa-responsive dystonia (GTPCH1-deficient DRD)	AD Dystonia w/motor delay (See GTPCH1-Deficient DRD, Genetically Related Disorders.)	AR
PTS	Hyperphenylalaninemia, BH4 deficient, A (See PTS-Related Tetrahydrobiopterin Deficiency.)	AR	—
QDPR	Hyperphenylalaninemia, BH4 deficient, C (OMIM 261630)	AR	—
SLC18A2	Infantile-onset parkinsonism-dystonia 2 (OMIM 618049)	AR SPR	Sepiapterin reductase deficiency
Primary pyruvate dehydrogenase complex deficiency	XLAR3	The phenotypic features of the mitochondriocytopathies overlap w/SLC6A3-related DTDS.4 HVA levels are also observed in some mitochondrial disorders.5 See also Primary Mitochondrial Disorders Overview. PC	Pyruvate carboxylase deficiency
POLG	AR POLG-related disorders	AR Metabolic syndromes including:	—
CBS	Homocystinuria caused by cystathionine beta-synthase deficiency (classic homocystinuria)	AR	Metabolic syndromes incl lysosomal storage diseases can mimic SLC6A3-related DTDS.6
GLB1	GM1 gangliosidosis (See GLB1-Related Disorders.)	AR	—
HPRT1	Lesch-Nyhan disease (See HPRT1 Disorders.)	XL NPC1 NPC2	Niemann-Pick disease type C
PAH	Untreated phenylketonuria (See Phenylalanine Hydroxylase Deficiency.)	AR Monogenic movement disorders associated with infantile-onset dyskinesia/hyperkinesia including: ADCY5	—
ADCY5 dyskinesia	ADAR7	Monogenic movement disorders assoc w/infantile-onset dyskinesia/hyperkinesia may be reminiscent of early disease manifestations of classic early-onset SLC6A3-related DTDS.2 ATP1A3	ATP1A3-related neurologic disorders
ATP8A2	Cerebellar ataxia, impaired intellectual development, disequilibrium syndrome 4 (OMIM 615268)	AR	—
FOXG1	Rett syndrome, congenital variant (See FOXG1 Syndrome.)	AD GNAO1	GNAO1-related disorder

Source: GeneReviews — "SLC6A3-Related Dopamine Transporter Deficiency Syndrome"

GeneReviews

Management Guidelines

No clinical practice guidelines for SLC6A3-related dopamine transporter deficiency syndrome (DTDS) have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with a SLC6A3-related DTDS, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 3. SLC6A3-Related Dopamine Transporter Deficiency Syndrome: Recommended Evaluations Following Initial Diagnosis

System/Concern	Evaluation	Comment
Movement disorder	Neurologic assessment of the movement disorder	Orolingual dyskinesia
Gastrointestinal	Assess for vomiting, GERD, constipation.	—
Genetic counseling	By genetics professionals1	To obtain a pedigree inform affected persons their families re nature, MOI, implications of SLC6A3-related DTDS to facilitate medical personal decision making Family support resources
SLC6A3-Related Dopamine Transporter Deficiency Syndrome: Treatment of Manifestations Manifestation/Concern	Treatment	Considerations/Other Chorea/Dyskinesia

Source: GeneReviews — "SLC6A3-Related Dopamine Transporter Deficiency Syndrome"

SLC6A3-related dopamine transporter deficiency syndrome

Overview

Clinical Presentation

Clinical Guidance

Diagnosis

Diagnostic Criteria

Suggestive Findings

Clinical Findings

Treatment

Orphan Drug Designations

Prognosis

Surveillance Guidelines

Research Landscape

Recent Publications

Medical References

Subtypes

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is SLC6A3-related dopamine transporter deficiency syndrome?

What are the symptoms of SLC6A3-related dopamine transporter deficiency syndrome?

What causes SLC6A3-related dopamine transporter deficiency syndrome?

How is SLC6A3-related dopamine transporter deficiency syndrome diagnosed?

Are there treatments for SLC6A3-related dopamine transporter deficiency syndrome?

What complications can arise from SLC6A3-related dopamine transporter deficiency syndrome?

How does SLC6A3-related dopamine transporter deficiency syndrome affect daily life?

What is the prognosis for someone with SLC6A3-related dopamine transporter deficiency syndrome?

Are there any specific specialists that should be involved in the care of someone with SLC6A3-related dopamine transporter deficiency syndrome?

Differential Diagnosis

Management Guidelines

Clinical Guidance

Clinical Trials